Inari Medical price target lowered to $90 from $92 at Piper Sandler

Piper Sandler analyst Adam Maeder lowered the firm’s price target on Inari Medical to $90 from $92 and keeps an Overweight rating on the shares after the company reported Q2 results that beat consensus estimates and raised its full-year revenue guidance. The firm’s price target cut is due to the company’s increased diluted share count, note the analyst, whose current view remains that competitive concerns for Inari are “overblown.”